Key result
Ziprasidone links to weight loss and favorable metabolic effects versus olanzapine, without QTc differences.
Why the study?
The metabolic and cardiovascular effects of ziprasidone versus olanzapine in adults with schizophrenia and other psychoses were not well characterized.
Does ziprasidone compared to olanzapine improve metabolic parameters and QTc interval in adults with schizophrenia and other psychoses?
Cohort (n=191)
Does ziprasidone compared to olanzapine improve metabolic parameters and QTc interval in adults with schizophrenia and other psychoses?
Ziprasidone has a more favorable metabolic and weight profile compared to olanzapine in patients with schizophrenia, with neither drug significantly prolonging the QTc interval.
Answers are grounded in this paper and cite their sources.
May inform antipsychotic selection to limit metabolic risk; leaves open need for prospective cardiovascular outcome trials.
This study aimed to examine the impact of ziprasidone and olanzapine on QTc interval, weight and metabolic parameters in adults with schizophrenia and other psychoses. A retrospective cohort chart review was performed of 191 randomly selected patients who were being treated with ziprasidone or olanzapine in an integrated health care system. Significant differences on QTc interval were not observed. A significant weight gain was observed in olanzapine-treated patients (P<0.001) but not in the ziprasidone-treated cohort (P>0.05). Furthermore, adverse metabolic changes associated with olanzapine administration were significant with respect to effects on total cholesterol (P=0.01), triglycerides (P=0.05) and haemoglobin A1C (HbA1C) (P<0.05), whereas significant favourable metabolic effects were observed in ziprasidone-treated patients with regard to total cholesterol (P<0.05), low-density lipoprotein (LDL) (P<0.01), high-density lipoprotein (HDL) (P<0.05) and HbA1c (P<0.05). Our results suggest that these two atypical antipsychotics are safe and well tolerated from a cardiovascular standpoint, with no differences in QTc interval prolongation being observed. Olanzapine-treated patients exhibited significant weight increases, whereas ziprasidone-treated patients exhibited weight loss. Olanzapine treatment was also associated with significant adverse effect on patient's lipid profile and HbA1c. These adverse metabolic effects were not observed in ziprasidone-treated patients although favourable effects were observed with regard to effect on total cholesterol, LDL, HDL and HbA1c.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2005) conducted a cohort in Schizophrenia and other psychoses (n=191). Ziprasidone vs. Olanzapine was evaluated on QTc interval, weight, and metabolic parameters. Ziprasidone was associated with weight loss and favorable metabolic effects, whereas olanzapine caused significant weight gain and adverse lipid and HbA1c changes, with no QTc differences.
Synapse has enriched 10 related papers. Consider them for comparative context: